These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 6271823)

  • 1. The metabolism of delta 9-tetrahydrocannabinol and related cannabinoids in man.
    Wall ME; Perez-Reyes M
    J Clin Pharmacol; 1981; 21(S1):178S-189S. PubMed ID: 6271823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women.
    Wall ME; Sadler BM; Brine D; Taylor H; Perez-Reyes M
    Clin Pharmacol Ther; 1983 Sep; 34(3):352-63. PubMed ID: 6309462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cytochrome P450 isozyme having aldehyde oxygenase activity plays a major role in metabolizing cannabinoids by mouse hepatic microsomes.
    Watanabe K; Narimatsu S; Matsunaga T; Yamamoto I; Yoshimura H
    Biochem Pharmacol; 1993 Aug; 46(3):405-11. PubMed ID: 8394082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma and brain levels of delta 6-THC and seven monooxygenated metabolites correlated to the cataleptic effect in the mouse.
    Ohlsson A; Widman M; Carlsson S; Ryman T; Strid C
    Acta Pharmacol Toxicol (Copenh); 1980 Oct; 47(4):308-17. PubMed ID: 6258385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of repeated administration of 11-hydroxy-delta 8-tetrahydrocannabinol, an active metabolite of delta 8-tetrahydrocannabinol, on the hepatic microsomal drug-metabolizing enzyme system of mice.
    Watanabe K; Arai M; Narimatsu S; Yamamoto I; Yoshimura H
    Biochem Pharmacol; 1986 Jun; 35(11):1861-5. PubMed ID: 3013200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg Delta9-THC.
    Ménétrey A; Augsburger M; Favrat B; Pin MA; Rothuizen LE; Appenzeller M; Buclin T; Mangin P; Giroud C
    J Anal Toxicol; 2005; 29(5):327-38. PubMed ID: 16105257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Further studies on the oxidative cleavage of the pentyl side-chain of cannabinoids: identification of new biotransformation pathways in the metabolism of 3'-hydroxy-delta-9-tetrahydrocannabinol by the mouse.
    Harvey DJ
    Xenobiotica; 1989 Dec; 19(12):1437-47. PubMed ID: 2559552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism and autoradiographic distribution of delta-8- and delta-9-tetrahydrocannabinol in some organs of the monkey Callithrix jacchus.
    Just WW; Erdmann G; Thel S; Werner G; Wiechmann M
    Naunyn Schmiedebergs Arch Pharmacol; 1975; 287(2):219-25. PubMed ID: 806815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the beta-oxidative metabolism of delta 1- and delta 6-tetrahydrocannabinol in the mouse. The in vivo biotransformation of metabolites oxidized in the side chain.
    Harvey DJ; Leuschner JT
    Drug Metab Dispos; 1985; 13(2):215-9. PubMed ID: 2859171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal Physiologically Based Pharmacokinetic Model of Intravenously and Orally Administered Delta-9-Tetrahydrocannabinol in Healthy Volunteers.
    Wolowich WR; Greif R; Kleine-Brueggeney M; Bernhard W; Theiler L
    Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):691-711. PubMed ID: 31114948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of Synthetic Cannabinoids JWH-210, RCS-4 and Δ 9-Tetrahydrocannabinol After Intravenous Administration to Pigs.
    Schaefer N; Kettner M; Laschke MW; Schlote J; Ewald AH; Menger MD; Maurer HH; Schmidt PH
    Curr Neuropharmacol; 2017; 15(5):713-723. PubMed ID: 27834143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3H-delta 9-Tetrahydrocannabinol, 3H-cannabinol and 3H-cannabidiol: penetration and regional distribution in rat brain.
    Alozie SO; Martin BR; Harris LS; Dewey WL
    Pharmacol Biochem Behav; 1980 Feb; 12(2):217-21. PubMed ID: 6246544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Forensic aspects of the metabolism and excretion of cannabinoids following oral ingestion of cannabis resin.
    Law B; Mason PA; Moffat AC; Gleadle RI; King LJ
    J Pharm Pharmacol; 1984 May; 36(5):289-94. PubMed ID: 6145762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of cannabinoids.
    McGilveray IJ
    Pain Res Manag; 2005; 10 Suppl A():15A-22A. PubMed ID: 16237477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary excretion half-life of delta 1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking.
    Johansson E; Halldin MM
    J Anal Toxicol; 1989; 13(4):218-23. PubMed ID: 2550702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of in vivo liver metabolites of delta 1-tetra-hydrocannabinol, cannabidiol, and cannabinol produced by the guninea-pig.
    Harvey DJ; Martin BR; Paton WD
    J Pharm Pharmacol; 1980 Apr; 32(4):267-71. PubMed ID: 6103056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism of n-hexyl-homologues of delta-8-tetrahydrocannabinol and delta-9-tetrahydrocannabinol in the mouse.
    Brown NK; Harvey DJ
    Eur J Drug Metab Pharmacokinet; 1988; 13(3):165-76. PubMed ID: 2853671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A vapourized Δ(9)-tetrahydrocannabinol (Δ(9)-THC) delivery system part I: development and validation of a pulmonary cannabinoid route of exposure for experimental pharmacology studies in rodents.
    Manwell LA; Charchoglyan A; Brewer D; Matthews BA; Heipel H; Mallet PE
    J Pharmacol Toxicol Methods; 2014; 70(1):120-7. PubMed ID: 24973534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man.
    Hunt CA; Jones RT; Herning RI; Bachman J
    J Pharmacokinet Biopharm; 1981 Jun; 9(3):245-60. PubMed ID: 6270295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers.
    Atsmon J; Cherniakov I; Izgelov D; Hoffman A; Domb AJ; Deutsch L; Deutsch F; Heffetz D; Sacks H
    J Pharm Sci; 2018 May; 107(5):1423-1429. PubMed ID: 29287930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.